10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation

Transplant International

Volumn 29, Issue 1, 2016, Pages 51-62

  Peghin, Maddalena ^a,b   Monforte, Victor ^a,c   Martin Gomez, Maria Teresa ^a   Ruiz Camps, Isabel ^a,b   Berastegui, Cristina ^a,c   Saez, Berta ^a,c   Riera, Jordi ^a   Ussetti, Piedad ^d   Solé, Juan ^a   Gavaldá, Joan ^a,b   Roman, Antonio ^a,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

antifungal prophylaxis; fungal infections; invasive aspergillosis; lung transplant; nebulized liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN; VORICONAZOLE; AMPHOTERICIN B;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOMA; ASPERGILLOSIS; ASPERGILLUS ALLIACEUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS TERREUS; CHEMOPROPHYLAXIS; CHRONIC LUNG ALLOGRAFT DYSFUNCTION; CONTROLLED STUDY; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; FUNGAL COLONIZATION; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LONG TERM CARE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NEBULIZATION; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRACHEOBRONCHITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; ADVERSE EFFECTS; ASPERGILLUS; BACTERIAL COUNT; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; MORTALITY; POSTOPERATIVE COMPLICATIONS; PRIMARY PREVENTION; PROCEDURES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTOR;

ADMINISTRATION, INHALATION; ADULT; AMPHOTERICIN B; ASPERGILLOSIS; ASPERGILLUS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84953438776     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12679     Document Type: Article

References (36)

1. Pappas PG, Alexander BD, Andes DR, et al,. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101.
2. Neofytos D, Fishman JA, Horn D, et al,. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: 220.
3. Bhaskaran A, Mumtaz K, Husain S,. Anti-aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep 2013; 15: 514.
4. Monforte V, Roman A, Gavalda J, et al,. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20: 1274.
5. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP,. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005; 52: 15.
6. Monforte V, Ussetti P, Gavalda J, et al,. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29: 523.
7. Monforte V, Ussetti P, Lopez R, et al,. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28: 170.
8. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR,. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232.
9. Lowry CM, Marty FM, Vargas SO, et al,. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007; 9: 121.
10. Monforte V, Lopez-Sanchez A, Zurbano F, et al,. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J Heart Lung Transplant 2013; 32: 313.
11. De Pauw B, Walsh TJ, Donnelly JP, et al,. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813.
12. Husain S, Mooney ML, Danziger-Isakov L, et al,. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011; 30: 361.
13. Valentine VG, Bonvillain RW, Gupta MR, et al,. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant 2008; 27: 528.
14. Singh N, Husain S, Practice ASTIDCo. Aspergillosis in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 228.
15. Gavalda J, Len O, San Juan R, et al,. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52.
16. Herbrecht R, Denning DW, Patterson TF, et al,. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408.
17. Husain S, Paterson DL, Studer S, et al,. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008.
18. Eriksson M, Lemstrom K, Suojaranta-Ylinen R, et al,. Control of early Aspergillus mortality after lung transplantation: outcome and risk factors. Transpl Proc 2010; 42: 4459.
19. Hayes D Jr, Ball AM, Mansour HM, Martin CA, Flynn JD,. Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole. Exp Clin Transplant 2011; 9: 399.
20. Cadena J, Levine DJ, Angel LF, et al,. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9: 2085-91.
21. Mitsani D, Nguyen MH, Shields RK, et al,. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56: 2371.
22. Singh N, Limaye AP, Forrest G, et al,. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 2006; 44: 445.
23. Neoh CF, Snell GI, Kotsimbos T, et al,. Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant 2011; 11: 361.
24. Alastruey-Izquierdo A, Mellado E, Pelaez T, et al,. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013; 57: 3380.
25. Garcia-Vidal C, Royo-Cebrecos C, Peghin M, et al,. Environmental variables associated with an increased risk of invasive aspergillosis. Clin Microbiol Infect 2014; 20: O939.
26. Alastruey-Izquierdo A, Gomez-Lopez A, Arendrup MC, et al,. Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol 2012; 50: 2509.
27. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP,. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003; 46: 25.
28. Caston JJ, Linares MJ, Gallego C, et al,. Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for filamentous fungi. Chest 2007; 131: 230.
29. Cahill BC, Hibbs JR, Savik K, et al,. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160.
30. Sole A, Morant P, Salavert M, Peman J, Morales P, Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005; 11: 359.
31. Monforte V, Roman A, Gavalda J, et al,. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571-4.
32. Weigt SS, Elashoff RM, Huang C, et al,. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1903.
33. Weigt SS, Copeland CA, Derhovanessian A, et al,. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant 2013; 13: 919-27.
34. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR,. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915.
35. Paugam A, Baixench MT, Demazes-Dufeu N, et al,. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010; 48 (Suppl 1): S32.
36. Muller FM, Seidler M, Beauvais A,. Aspergillus fumigatus biofilms in the clinical setting. Med Mycol 2011; 49 (Suppl 1): S96.